Retroviral vector targeting for gene therapy

Cytokines and Molecular Therapy

Volumn 2, Issue 3, 1996, Pages 177-184

  Günzburg, Walter H ^a   Fleuchaus, Andrea ^a,b   Salier, Robert ^a,c   Salmons, Brian ^b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Bavarian Nordic GmbH   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Envelope; Expression; Gene delivery; Gene therapy; Heterologous promoter; Infection; Liver; Mammary gland; Pancreas; Pseudotyping; Receptor; Retroviral vector; Targeting; Tissue specificity

Indexed keywords

VIRUS ENVELOPE PROTEIN;

CONFERENCE PAPER; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; LIVER; MAMMARY GLAND; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS; VIRUS INFECTIVITY; VIRUS RECOMBINANT;

ANIMALS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LEUKEMIA VIRUS, MURINE; LIVER; MAMMARY GLANDS, ANIMAL; MICE; PANCREAS; PROMOTER REGIONS (GENETICS); RETROVIRIDAE;

EID: 0029835471     PISSN: 13556568     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Culver KW, Blaese RM, Gene therapy for cancer. Trends Genet (1994) 10: 174-8.
2. Günzburg WH, Salmons B, Virus vector design in gene therapy. Mol Med Today (1995) 1: 410-17.
3. Günzburg WH, Salmons B, Development of retroviral vectors as safe, targeted gene delivery systems. J Mol Med (1996) 74: 171-82.
4. McLachlin JR, Cornetta K, Eglitis MA, Anderson WF, Retroviral-mediated gene transfer. Prog Nucleic Acid Res Mol Biol (1990) 38: 91-135.
5. Salmons B, Günzburg WH, Targeting of retroviral vectors for gene therapy. Hum Gene Ther (1993) 4: 129-41.
6. Goff SP, Genetics of retroviral integration. Annn Rev Genet (1992) 26: 527-44.
7. Weiss RA, Tailor CS, Retrovirus receptors. Cell (1995) 82: 531-3.
8. Miller DG, Miller AD, A family of retroviruses that utilize related phosphate transporters for cell entry. J Virol (1994) 68: 8270-6.
9. van Zeijl M, Johann SV, Gloss E et al, A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family. Proc NatlAcadSci USA (1994) 91: 1168-72.
10. Battini J-L, Danos O, Heard JM, Receptor-binding domain of murine leukemia virus envelope. J Virol (1995) 69: 713-19.
11. Ott D, Rein A, Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU. J Virol (1992) 66: 4632-8.
12. Morgan RA, Nussbaum O, Muenchau DD et al, Analysis of the functional and host range-determining regions of the murine ecotropic and amphotropic retrovirus envelope proteins. J Virol (1993) 67: 4712-21.
13. Kasahara N, Dozy AM, Kan YW, Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science (1994) 266: 1373-6.
14. Han X, Kasahara N, Kan YW, Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl AcadSci USA (1995) 92: 9747-51.
15. Valsesia-Wittmann S, Drynda A, Deleage G et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host-range of retroviral vectors. J Virol (1994) 68: 4609-19.
16. Russell SJ, Hawkins RE, Winter G, Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res (1993) 21: 1081-5.
17. Chu T-HT, Dornburg R, Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol (1995) 69: 2659-63.
18. Somia NV, Zoppe M, Verma IM, Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sei USA (1995) 92: 7570-4.
19. Cosset FL, Morling FJ, Takeuchi Y et al, Retroviral retargeting by envelopes expressing an N-terminal binding domain, jf Virol (1995) 69: 6314-22.
20. Etienne-Julan M, Roux P, Carillo S et al, The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol (1992) 73: 3251-5.
21. Nilson BHK, Morling FJ, Peng KW et al, Exploiting the process of cancer invasion for promotion of retrovirus entry. Gene Ther (1995) 2(suppl 1): S21.
22. Friedmann T, Yee J-K, Pseudotyped retroviral vector for studies of human gene therapy. Nature Med (1995) 1: 275-7.
23. Burns JC, Friedmann T, Driever W et al, Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sei USA (1993) 90: 8033-7.
24. Yee JK, Friedmann T, Burns JC, Generation of hightiter pseudotyped retroviral vectors with very broad host range. Meth Cell Biol (1994) 43: 99-112.
25. Salmons B, Sailer RM, Baumann J, Günzburg WH, Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia (1995) 9(suppl 1): 53-60.
26. Xu L, Yee JK, Wolff JA, Friedmann T, Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology (1989) 171: 331-41.
27. Duch M, Paludan K, Jorgensen P, Pederson FS, Lack of correlation between basal expression levels and susceptibility of transcriptional shutdown among single-gene murine leukemia virus vector proviruses. J F/ro/(1994) 68: 5596-601.
28. Majors J, The structure and function of retroviral long terminal repeats. Ciirr Top Microbiol Immimol (1990) 157:49-92.
29. Honvitz AL, Inherited hepatic enzyme defects as candidates for liver-directed gene therapy. Ciirr Top Microbiol Immimol (\99\~) 168: 185-200.
30. Strauss M, Liver-directed gene therapy: prospects and problems. Gene 77;er(1994) 1: 156-64.
31. Kay MA, Woo SLC, Gene therapy for metabolic disorders. Trends Genet (1994) 10: 253-7.
32. Hafenrichter DG, Wu XY, Rettinger SD et al, Quantitative evaluation of liver specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood (1994) 84: 3394-404.
33. Magnuson MA, Jetton TL, Evolutionary conservation of elements in the upstream glucokinase promoter Biochem Soc Trans (1993) 21: 160-3.
34. Cawson RA, McCracken AW, Marcus PB, Zaatari GS, Pathology. The mechanisms of disease. Mosby, St Louis, 1989.
35. Moesta KT, Schlag P, Douglass HO, Mang TS, Evaluating the role of photodynamic therapy in the management of pancreatic cancer. Lasers Siirg Med (195) 16: 84-92.
36. lynedjian PB, Mammalian glucokinase and its gene. Biochem J(1993) 293: 1-13.
37. Tashian RE, Genetics of the mammalian carbonic anhydrases. Adv Genet (1992) 30: 321-56.
38. Velander WH, Johnson JL, Page RL et al, High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sei USA (1992) 89: 12 003-7.
39. Hennighausen L, The mammary gland as a bioreactor: production of foreign proteins in milk. Protein Expression Purification (1990) 1: 3-8.
40. Günzburg WH, Salmons B, Zimmermann B et al, A mammary-specific promoter directs expression of growth hormone not only to the mammary gland but also to Bergman glia cells in transgenic mice. Mol Endocrinol (1991) 5: 123-33.
41. Kolb AF, Günzburg WH, Albang R et al, A négative regulatory element in the mammary specific whey acidic protein promoter. J Cell Biochem (1994) 55: 245-61.
42. Kolb AF, Albang R, Brem G et al, Characterization of a protein that binds a negative regulatory element in the mammary specific whey acidic protein promoter. Biochem Biophys Res Commun (1995) 217: 1045-52.
43. Günzburg WH, Salier R, Salmons B, Retroviral vectors directed to predefined cell types for gene therapy. Biologicak (1995) 23: 5-12.
44. Slamon DJ, Clark GM, Wong .SG et al, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235: 177-82.
45. Hall PA, Hughes CM, Staddon SL et al, The c-erbB2 proto-oncogene in human pancreatic cancer. J Patliol (1990) 161: 195-200.
46. Hollywood D, Hurst HC, A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO jf (1993) 12: 2369-75.
47. Harris JD, Gutierrez AA, Hurst HC et al, Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther (1994) 1: 170-5.
48. Wickham TJ, Carrion ME, Kovesdi I, Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptorspecific peptide motifs. Gene Ther (1995) 2: 750-6.
49. Friedman JM, Babiss LE, Clayton DF, Darnell JE, Cellular promoters incorporated into the adenovirus genome: cell specificity of albumin and immunoglobulin expression. Mol Cell Biol (1986) 6: 3791-7.